NCT03600155View on ClinicalTrials.gov

Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 11, 2018

Primary Completion Date

December 2, 2024

Study Completion Date

December 2, 2024

Conditions

Allogeneic Hematopoietic Stem Cell Transplantation RecipientMyelodysplastic SyndromeRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia

Interventions

BIOLOGICAL

Ipilimumab

Given IV

BIOLOGICAL

Nivolumab

Given IV

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT03600155 - Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome | Biotech Hunter | Biotech Hunter